Aslan Pharmaceuticals Ltd
Change company Symbol lookup
Select an option...
ASLN Aslan Pharmaceuticals Ltd
WHR Whirlpool Corp
BAC Bank of America Corp
ARI Apollo Commercial Real Estate Finance Inc
ISNPY Intesa Sanpaolo SpA
BRKR Bruker Corp
AHT-F Ashford Hospitality Trust Inc
ZS Zscaler Inc
UNIT Uniti Group Inc
HENGY Hengdeli Holdings Ltd
Go

Health Care : Biotechnology |
Based in Singapore
Company profile

ASLAN Pharmaceuticals Limited (ASLAN) is a clinical-stage immunology and oncology-focused biopharmaceutical company. ASLAN has a clinical portfolio comprised of a first in class monoclonal therapy, ASLAN004, that is being developed in atopic dermatitis and other immunology indications, and a small molecule inhibitor targeting oncology.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Closing Price
$2.17
Day's Change
0.03 (1.40%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.18
Day's Low
2.10
Volume
(Average)
Volume:
247,869

10-day average volume:
268,537
247,869

Upcoming Events

ASLN's fiscal year ends in December
There are no upcoming events for ASLN

Past Earnings

This page reports .
DateEvent descriptionEarnings per
share actual
Earnings
estimate range
Previous year's
actual
November 9, 2020Q3 2020 Earnings Release-$0.10-$0.10 to -$0.09-$0.15
July 21, 2020Q2 2020 Earnings Release-$0.104-$0.11 to -$0.02-$0.248
May 11, 2020Q1 2020 Earnings Release-$0.10-$0.12 to -$0.02-$0.135
March 18, 2020Q4 2019 Earnings Release-$0.90-$0.19 to -$0.15--

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

, , , Copyright © 2021. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.